<Disease><Name>PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY (PRPPS)</Name><Synonym>PRPS1 SUPERACTIVITY</Synonym><OMIM><Number>300661</Number><URL>http://omim.org/entry/300661</URL></OMIM><Orphanet><Number>3222</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=3222</URL></Orphanet><Protein><Number>Ribose-phosphate diphosphokinase (Phosphoribosyl pyrophosphate synthetase)</Number><URL>http://www.uniprot.org/uniprot/P60891</URL></Protein><ExPASy><Number>2.7.6.1</Number><URL>http://enzyme.expasy.org/EC/2.7.6.1</URL></ExPASy><Gene>Xq22.3</Gene><ICD>E79.8</ICD><Summary>rare ;X-linked recessive;mutations in the X-chromosomal gene PRPS1;- infantile or early-childhood onset (severe phenotype);- late-juvenile or early-adult onset (milder phenotype)</Summary><Symptoms><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3819</id><symptom>developmental delay</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2227</id><symptom>dysmorphism / dysmorphic features</symptom><category>HEAD</category></symtomp><symtomp><id>1950</id><symptom>gout</symptom><category>ENDOCRINE SYSTEM | SKELETAL DEFECT</category></symtomp><symtomp><id>2433</id><symptom>hearing defect, deafness</symptom><category>EARS | NERVOUS SYSTEM</category></symtomp><symtomp><id>3926</id><symptom>hyperuricemia</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1897</id><symptom>hypotonia</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1715</id><symptom>infections (severe or recurrent)</symptom><category>GENERAL TOPICS | IMMUNE OR HEMATOLOGIC SYSTEM</category></symtomp><symtomp><id>3826</id><symptom>intellectual disability/intellectual developmental disorder</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1941</id><symptom>motor retardation / motor developmental delay</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2506</id><symptom>onset, adolescent / adolescence</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1739</id><symptom>optic atrophy</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2461</id><symptom>renal failure, acute/chronic</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>2236</id><symptom>urolithiasis, nephrolithiasis, kidney stones</symptom><category>GENITOURINARY TRACT</category></symtomp></Symptoms><Metabolites><metabolite><id>1671</id><name>Oxypurinol (Allopurinol-metabolite)</name><specimen>urine</specimen><value>normal/inc</value><min>5.10</min><max>29.30</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1839</id><name>Oxypurinol (Allopurinol-metabolite)</name><specimen>urine</specimen><value>normal/inc</value><min>19.00</min><max>37.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1536</id><name>Hypoxanthine</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>88.10</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>1537</id><name>Hypoxanthine</name><specimen>urine</specimen><value>increased</value><min>1.80</min><max>24.10</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1068</id><name>Hypoxanthine</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>71.90</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method>HPLC</method><comment /></metabolite><metabolite><id>1067</id><name>Hypoxanthine</name><specimen>plasma</specimen><value>increased</value><min>0.00</min><max>10.00</max><unit>&#956;mol/l</unit><age>all</age><method /><comment /></metabolite><metabolite><id>1996</id><name>Hypoxanthine</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>71.90</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>451</id><name>Uric acid</name><specimen>urine</specimen><value>increased</value><min>527.00</min><max>790.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1535</id><name>Uric acid</name><specimen>urine</specimen><value>increased</value><min>222.00</min><max>287.00</max><unit>mmol/mol creatinine</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>776</id><name>Uric acid</name><specimen>urine</specimen><value>increased</value><min>820.00</min><max>1026.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>417</id><name>Uric acid</name><specimen>serum</specimen><value>increased</value><min>120.00</min><max>350.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>5986</id><title>Novel PRPS1 gain-of-function mutation in a patient with congenital hyperuricemia and facial anomalies</title><author>Porrmann J,</author><journal>Am J Med Genet A</journal><year>2017</year><book /><volume>173</volume><number>10</number><pages>2736-2742</pages><co_aut>et al.</co_aut></literature><literature><id>5032</id><title>Phosphoribosylpyrophosphate Synthetase Superactivity</title><author>de Brouwer APM,</author><journal>GeneReviews&#174; [Internet]</journal><year>2015</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Duley JA, Christodoulou J</co_aut></literature><literature><id>5983</id><title>Phosphoribosylpyrophosphate synthetase superactivity and recurrent infections is caused by a p.Val142Leu mutation in PRS-I</title><author>Moran R,</author><journal>Am J Med Genet A</journal><year>2012</year><book /><volume>158</volume><number>2</number><pages>455-450</pages><co_aut>et al.</co_aut></literature><literature><id>2147</id><title>Inherited hyperuricemic disorders</title><author>Nyhan WL</author><journal>Contrib Nephrol</journal><year>2005</year><book /><volume>147</volume><number>0</number><pages>22-34</pages><co_aut /></literature><literature><id>2148</id><title>Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman</title><author>Garcia-Pavia P</author><journal>Arthritis Rheum</journal><year>2003</year><book /><volume>48</volume><number>7</number><pages>2036-2041</pages><co_aut>et al.</co_aut></literature><literature><id>2149</id><title>Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase</title><author>Ahmed M</author><journal>J Biol Chem</journal><year>1999</year><book /><volume>274</volume><number>11</number><pages>7482-7488</pages><co_aut>et al.</co_aut></literature><literature><id>771</id><title>Disorders of purine and pyrimidine metabolism</title><author>van den Berghe G</author><journal>in Fernandes J, Saudubray JM, van den Berghe (eds): Inborn metabolic diseases, diagnosis and treatment; Berlin, Springer Verlag</journal><year>1996</year><book /><volume>0</volume><number>0</number><pages>289-302</pages><co_aut>Vincent MF</co_aut></literature></Literatures></Disease>